Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Vladimı́r Tesař et al.|The Lancet|2023Cited by 264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J.L. Heerspink, Toby Coates, Jai Radhakrishnan et al.|The Lancet|2023Cited by 214
Mesenchymal Stem Cells Modulate Albumin-Induced Renal Tubular Inflammation and FibrosisHao Wu, Sydney Tang|PLoS ONE|2014Cited by 80
Bradykinin and high glucose promote renal tubular inflammationSydney Tang, K.N. Lai|Nephrology Dialysis Transplantation|2009Cited by 75
Vaccination in patients with chronic kidney disease—Review of current recommendations and recent advancesBecky Mingyao, Tak Mao Chan, Desmond Y. H. Yap et al.|Nephrology|2020Cited by 57